Kota Toshimoto

578 total citations
22 papers, 411 citations indexed

About

Kota Toshimoto is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Kota Toshimoto has authored 22 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pharmacology and 5 papers in Molecular Biology. Recurrent topics in Kota Toshimoto's work include Drug Transport and Resistance Mechanisms (15 papers), Pharmacogenetics and Drug Metabolism (13 papers) and Liver Disease Diagnosis and Treatment (5 papers). Kota Toshimoto is often cited by papers focused on Drug Transport and Resistance Mechanisms (15 papers), Pharmacogenetics and Drug Metabolism (13 papers) and Liver Disease Diagnosis and Treatment (5 papers). Kota Toshimoto collaborates with scholars based in Japan, South Korea and United States. Kota Toshimoto's co-authors include Yuichi Sugiyama, Takashi Yoshikado, Wooin Lee, Kazuya Maeda, Hiroyuki Kusuhara, Ken‐ichi Nunoya, Kōji Chiba, Emi Kimoto, A. David Rodrigues and Yasunori Aoki and has published in prestigious journals such as Pharmaceutical Research, Journal of Pharmaceutical Sciences and Drug Metabolism and Disposition.

In The Last Decade

Kota Toshimoto

22 papers receiving 405 citations

Peers

Countries citing papers authored by Kota Toshimoto

Since Specialization

Citations

This map shows the geographic impact of Kota Toshimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kota Toshimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kota Toshimoto more than expected).

Fields of papers citing papers by Kota Toshimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kota Toshimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kota Toshimoto. The network helps show where Kota Toshimoto may publish in the future.

Co-authorship network of co-authors of Kota Toshimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kota Toshimoto. A scholar is included among the top collaborators of Kota Toshimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kota Toshimoto. Kota Toshimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models 2024 ·Drug Metabolism and Pharmacokinetics ·Kota Toshimoto	4
2	Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology 2024 ·Drug Metabolism and Pharmacokinetics ·(unknown), (unknown), Kota Toshimoto, Takeshi Nakayama, (unknown)	3
3	Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Shinji Nakayama, Kota Toshimoto, Shinji Yamazaki, Jan Snoeys, Yuichi Sugiyama	3
4	Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy 2021 ·Drug Metabolism and Disposition ·(unknown), Kota Toshimoto, Wooin Lee, Yasunori Aoki, Yuichi Sugiyama	13
5	Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1B 2020 ·Journal of Pharmaceutical Sciences ·Ji Eun Park, Yoshihisa Shitara, Wooin Lee, (unknown), Jasminder Sahi, Kota Toshimoto, Yuichi Sugiyama	6
6	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes 2020 ·Journal of Pharmaceutical Sciences ·Takashi Yoshikado, Wooin Lee, Kota Toshimoto, (unknown), (unknown), Xiaoyan Chu, Nora Lee, Emi Kimoto, Manthena V. S. Varma, Ryota Kikuchi, Renato J. Scialis, Hong Shen, Naoki Ishiguro, Ralf Lotz, Albert P. Li, Kazuya Maeda, Hiroyuki Kusuhara, Yuichi Sugiyama	9
7	Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine 2019 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Kota Toshimoto, Wooin Lee, Naoki Ishiguro, Bojan Bister, Yuichi Sugiyama	29
8	Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin 2018 ·Drug Metabolism and Disposition ·(unknown), Kota Toshimoto, Takashi Yoshikado, Yuichi Sugiyama, Yukio Kato	14
9	In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines 2018 ·Pharmaceutical Research ·(unknown), Kota Toshimoto, Kazuya Maeda, (unknown), Takashi Ishida, Yutaka Akiyama, Yuichi Sugiyama	11
10	Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake 2018 ·European Journal of Pharmaceutical Sciences ·(unknown), (unknown), Shinsuke Aoyama, Kazuya Maeda, Kiyomi Ito, Kota Toshimoto, Wooin Lee, Shinichi Ninomiya, Yuichi Sugiyama	16
11	Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics 2018 ·Drug Metabolism and Disposition ·Masanobu Sato, Kota Toshimoto, (unknown), Takashi Yoshikado, Y. Tanaka, Akihiro Hisaka, Wooin Lee, Yuichi Sugiyama	19
12	Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling 2018 ·Drug Metabolism and Disposition ·(unknown), Kota Toshimoto, Soojin Kim, Takashi Yoshikado, Yuichi Sugiyama	15
13	Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen 2018 ·CPT Pharmacometrics & Systems Pharmacology ·Toshimichi Nakamura, Kota Toshimoto, Wooin Lee, Chiyo K. Imamura, Yusuke Tanigawara, Yuichi Sugiyama	10
14	Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects 2018 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Kota Toshimoto, (unknown), (unknown), Ken‐ichi Nunoya, (unknown), Wooin Lee, Yuichi Sugiyama	51
15	Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug–Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling 2017 ·Journal of Pharmaceutical Sciences ·Kota Toshimoto, (unknown), Kōji Chiba, Yuichi Sugiyama	6
16	Quantitative Analysis of Complex Drug–Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data 2017 ·Journal of Pharmaceutical Sciences ·Soojin Kim, Kota Toshimoto, (unknown), Takashi Yoshikado, Yuichi Sugiyama	17
17	Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects 2017 ·Pharmaceutical Research ·Kota Toshimoto, (unknown), Masakiyo Hosokawa, Yuichi Sugiyama	20
18	Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins 2017 ·Drug Metabolism and Disposition ·Takashi Yoshikado, Kota Toshimoto, Tomohisa Nakada, (unknown), Hiroyuki Kusuhara, Kazuya Maeda, Yuichi Sugiyama	44
19	Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism 2017 ·Journal of Pharmaceutical Sciences ·(unknown), Kota Toshimoto, Takanori Mori, (unknown), (unknown), Takeshi Sawada, (unknown), (unknown), Yoshitaka Hashimoto, Ken‐ichi Nunoya, (unknown), Seiji Miyauchi, (unknown)	29
20	Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure 2016 ·Journal of Pharmaceutical Sciences ·Atsushi Ose, Kota Toshimoto, Kazushi Ikeda, Kazuya Maeda, (unknown), Fumiyoshi Yamashita, Mitsuru Hashida, Takashi Ishida, Yutaka Akiyama, Yuichi Sugiyama	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact